Results 71 to 80 of about 8,082 (209)

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1303-1304, June 2026.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post‐Marketing Surveillance Sub‐Analysis

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Thrombotic events (TEs) account for approximately 40%–67% of deaths in untreated paroxysmal nocturnal haemoglobinuria (PNH). C5 inhibitor treatment (e.g., eculizumab and ravulizumab) greatly reduces the incidence of TEs in patients with PNH, but data on the characteristics of PNH patients experiencing TEs are limited.
Takayuki Ikezoe, Tatsuya Kawaguchi, Hideo Hayashi, Akihiko Shimono, Jun‐ichi Nishimura   +4 more
wiley   +1 more source

Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm

, 2016
Yarden S Fraiman,1,2 Nathan Cuka,3 Denise Batista,3 Milena Vuica-Ross,3 Alison R Moliterno4 1Department of Pediatrics, Harvard Medical School, 2Department of Pediatrics, Boston University School of Medicine, Boston, MA, 3Department of Pathology ...
Cuka N, Batista D, Moliterno AR, Fraiman YS, Vuica-Ross M   +4 more
core  

Mandibular osteomyelitis associated with paroxysmal nocturnal hemoglobinuria

, 2011
A case of osteomyelitis in a 71-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) is reported. Osteomyelitis of the jaw is a well known condition of the oral and maxillofacial region that may cause severe morbidity. It is well documented that
G. Warfvinge, Warfvinge, Gunnar, Carlson, Kristina,, Björnstad, L, Petersson, Arne, M. Kharazmi, Petersson, A, K. Carlson, Kharazmi, M, Petersson, Arne,, Kharazmi, Mohammad, Warfvinge, Gunnar,, Carlsson, Kristina, A. Petersson, Björnstad, Lillemor, L. Björnstad, Warfvinge, G   +16 more
core   +1 more source

Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents

, 2008
Antonio M Risitano, Bruno RotoliHematology, Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, ItalyAbstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal non-malignant hematological disease characterized ...
RISITANO, ANTONIO MARIA, Bruno Rotoli, Antonio M Risitano, Rotoli B.   +3 more
core  

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

Adult TWIST2‐high B‐ALL confirms metabolic association but reveals molecular heterogeneity

HemaSphere, Volume 10, Issue 6, June 2026.
Wencke Walter, Veronika Ecker, Wolfgang Kern, Anna Stengel   +3 more
wiley   +1 more source

Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria

Case Reports in Hematology, 2015
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive, and life-threatening hematopoietic stem cell disorder characterized by complement-mediated intravascular hemolysis and a prothrombotic state.
Pusem Patir, Yakup Isik, Yigit Turk, Mehmet Can Ugur, Cengiz Ceylan, Gulnur Gorgun, Nihal Mete Gokmen, Guray Saydam, Fahri Sahin   +8 more
doaj   +1 more source

Paroxysmal Nocturnal Hemoglobinuria Superimposed with Preeclampsia

Taiwanese Journal of Obstetrics & Gynecology, 2006
Objective: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement-mediated intravascular hemolysis. As maternal complication of PNH is already severe, it becomes much more complex when preeclampsia is ...
Mann-Ling Chen, Chen-Hsiang Yu, Fong-Ming Chang, Pao-Lin Kuo   +3 more
doaj   +1 more source

Severe cutaneous thrombosis with hemorrhagic necrosis in a patient with paroxysmal nocturnal hemoglobinuria: A case report and review of literature

Dermatologica Sinica, 2017
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic acquired clonal stem cell disorder, typically manifesting hemolysis, pancytopenia and thrombosis in various organs. PNH-associated cutaneous thrombosis is extremely rare.
Fu-Nien Hsieh, Tsai-Yun Chen, Julia Yu-Yun Lee   +2 more
doaj   +1 more source